DSP-0390 + Atezolizumab for Small Cell Lung Cancer

This trial explores a new combination treatment for individuals with extensive stage small cell lung cancer (ES-SCLC). Researchers aim to determine if adding DSP-0390, an experimental drug, to the existing treatment atezolizumab, an immune therapy, is safe and effective in controlling the cancer. The trial targets those whose cancer has not worsened after initial chemotherapy with immune therapy. Ideal participants have confirmed small cell lung cancer and have completed several cycles of initial treatment without cancer progression. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new drug.

You may need to stop taking certain medications, especially if they are strong or moderate CYP3A4 or CYP2D6 inhibitors or inducers. These should be discontinued at least 1 week or 5 half-lives before starting the trial. Always discuss with your doctor to ensure safety.

In other studies, atezolizumab has generally been safe. About 27.7% of patients experienced immune-related side effects like skin rash or diarrhea. Severe cases occurred in 9.9% of patients, and very severe cases in about 2.1%. This indicates that most people tolerate the treatment well.

Regarding DSP-0390, limited public information exists because it remains in early testing. The current study is in Phase 1, focusing on assessing the treatment's safety for humans. Scientists continue to learn about possible side effects.

Researchers are excited about DSP-0390 combined with Atezolizumab for treating small cell lung cancer because DSP-0390 introduces a new approach with its oral administration, making it potentially more convenient for patients than traditional intravenous chemotherapy. While most current treatments focus on targeting cancer cells directly, DSP-0390's unique mechanism might offer a different pathway to attack the cancer, potentially leading to better outcomes. Additionally, combining it with Atezolizumab, an immune checkpoint inhibitor, may enhance the body's immune response against the cancer, offering hope for improved effectiveness compared to existing treatments.

Research has shown that atezolizumab effectively treats extensive-stage small cell lung cancer (ES-SCLC). Studies have found that patients receiving atezolizumab with chemotherapy tend to live longer, with an average survival time of about 16.5 months in real-world situations. This trial investigates DSP-0390 for its potential to block cholesterol production, which might enhance treatment outcomes when combined with atezolizumab. Although information on DSP-0390 remains limited, combining it with atezolizumab appears promising based on these effects. Participants in this trial will receive varying doses of DSP-0390 alongside atezolizumab to determine the safest and most effective combination.¹⁵⁶⁷⁸